Herombopag Olamine

Phase 2Small molecule

FFujian Cancer Hospital

Herombopag Olamine is one of 121 small molecule programs targeting Herombopag. It is currently in Phase 2.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

HerombopagRecruiting

Efficacy and SafetyRecruiting

Nasopharyngeal CarcinomaNot yet recruiting

ThrombocytopeniaUnknown status

HerombopagPhase 2

Recruiting

Efficacy and SafetyPhase 2

Recruiting

Nasopharyngeal CarcinomaPhase 2

Not yet recruiting

ThrombocytopeniaPhase 2

Unknown status

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

HLX10

Shanghai Henlius Biotech

Phase 3

2 2

NTQ5082

NNanjing Chia-tai Tianqing Pharmaceutical

Phase 3

1 3

Zvs101e

CChigenovo Co., Ltd

Phase 3

1 4

IN-B00009

HHK inno.N Corporation

Phase 3

1 5

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 6

Herombopag Olamine

FFujian Cancer Hospital

Phase 2

1 7

VSA003

VVisirna Therapeutics HK Limited

Phase 3

1 8

Lenzumestrocel

CCorestemchemon, Inc.

Phase 3

1 9

Tribulus Terrestris

FFederal University of Minas Gerais

Phase 3

1 10

Onglyza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Herombopag

NCT07257809

Q4 2027

Phase 2Recruiting

Efficacy and Safety

NCT06838949

Q2 2028

Phase 2Not yet recruiting

Thrombocytopenia

NCT07243418

Q4 2028

Phase 2Not yet recruiting

Nasopharyngeal Carcinoma

NCT07252375

Clinical

Trials by Indication[1]

Thrombocytopenia4 trials

Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer

Unknown status·SSecond Hospital of Shanxi Medical University·N/A·NCT05160857·30 enrolled

A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia

Not yet recruiting·HHebei Medical University Fourth Hospital··NCT06376435·500 enrolled

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05252091·30 enrolled

Show 1 more trial

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07243418·72 enrolled

Herombopag3 trials

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06062680·15 enrolled

Herombopag Treated T-DM1 Induced Platelet Reduction

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07257809·56 enrolled

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06346925·18 enrolled

Nasopharyngeal Carcinoma1 trial

A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07252375·35 enrolled

Efficacy and Safety1 trial

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06838949·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Herombopag Olamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Herombopag Olamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Herombopag Olamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFujian Cancer Hospital

Herombopag Olamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Thrombocytopenia4 trials

Herombopag3 trials

Nasopharyngeal Carcinoma1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News